Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M98,280Revenue (TTM) $M37,776Net Margin (%)5.8Altman Z-Score1.3
Enterprise Value $M120,322EPS (TTM) $0.4Operating Margin %12.4Piotroski F-Score7
P/E(ttm)45.9Beneish M-Score-2.8Pre-tax Margin (%)10.1Higher ROA y-yY
Price/Book44.710-y EBITDA Growth Rate %-1.9Quick Ratio0.6Cash flow > EarningsY
Price/Sales2.65-y EBITDA Growth Rate %-8.7Current Ratio0.9Lower Leverage y-yY
Price/Free Cash Flow15.3y-y EBITDA Growth Rate %40.2ROA % (ttm)2.9Higher Current Ratio y-yN
Dividend Yield %5.1PEG--ROE % (ttm)132Less Shares Outstanding y-yN
Payout Ratio %235Shares Outstanding M4,918ROIC % (ttm)13.5Gross Margin Increase y-yY

Gurus Latest Trades with GLAXF

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

GLAXF is held by these investors:



GLAXF: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLCFormer 10% Owner 2015-02-23Sell503,150$22-9.55view
GLAXOSMITHKLINE PLC10% Owner 2014-12-18Sell50,000$21.14-5.87view
GLAXOSMITHKLINE PLCFormer 10% Owner (1) 2014-10-27Sell11,315,825$5.29276.18view
GLAXOSMITHKLINE PLC10% Owner 2014-04-01Buy103,762$1265.83view
GLAXOSMITHKLINE PLCFormer 10% Owner 2014-02-19Buy35,000$1442.14view
GLAXOSMITHKLINE PLCFormer 10% Shareholder 2014-02-10Buy143,773$1265.83view

Quarterly/Annual Reports about GLAXF:

    News about GLAXF:

    Articles On GuruFocus.com
    Pernix: An Investor's Rationale to Staying Long Mar 23 2017 
    Jeff Auxier Reduces, Exits Multiple Positions in 4th Quarter Mar 22 2017 
    Gilead Sciences Raises Dividend by Double Digits Feb 22 2017 
    If You Want Yield, Look to the UK Feb 19 2017 
    Flood of News Presents Buying Opportunity Jan 17 2017 
    Gilead Sciences Must Answer to Investors After a Disappointing 2016 Jan 05 2017 
    GlaxoSmithKline, Vodafone Hit 3-Year Low Prices Dec 24 2016 
    Asset Sales, New Projects Fuel 6.7% Yield Dec 07 2016 
    Robust Pipeline Supports 5.5% Dividend Yield Dec 05 2016 
    Jeff Auxier Curbs Multiple Positions in 3rd Quarter Dec 01 2016 

    More From Other Websites
    GlaxoSmithKline’s 1Q17 Earnings Surpass Analysts’ Estimates Apr 28 2017
    GlaxoSmithKline Plc :GLAXF-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017 Apr 28 2017
    Glaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View Apr 27 2017
    New GlaxoSmithKline CEO wants fewer, bigger new drug launches Apr 26 2017
    Analyst Ratings and Recommendations for GlaxoSmithKline Apr 26 2017
    Glaxo meets 1Q profit forecasts Apr 26 2017
    Ionis Pharmaceuticals: Big Data Coming Soon Apr 26 2017
    Glaxo Stock Slumps as Investors Eye Advair Generics Apr 26 2017
    Glaxo (GSK) Beats Earnings and Revenues in Q1 Apr 26 2017
    GlaxoSmithKline’s 1Q17 Estimates: Consumer Healthcare Apr 26 2017
    GlaxoSmithKline Beats Q1 Estimates, Keeps Full Year Targets In Place Apr 26 2017
    GSK warns of impact from generic drugs after solid Q1 Apr 26 2017
    [$$] GlaxoSmithKline Net Income Boosted by Strong Sales, Weak Pound Apr 26 2017
    Glaxo's New CEO Walmsley Pledges to Make Drugs the Priority Apr 26 2017
    Glaxo Profit Jumps 31% as Sales of HIV, Lung Drugs Increase Apr 26 2017
    Weak sterling boosts GlaxSmithKline as new CEO takes over Apr 26 2017
    [$$] GlaxoSmithKline 1Q Results Expected to Get Boost From Weak Pound Apr 25 2017
    GlaxoSmithKline’s 1Q17 Estimates: Revenues Expected to Grow Apr 25 2017
    GlaxoSmithKline’s 1Q17 Earnings: Analysts’ Estimates Apr 25 2017
    Drug Stocks Q1 Earnings Releases on Apr 26: AMGN, GSK & More Apr 25 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)